More than 6 million people in the United States take OACs.1 The most common indications for OACs are atrial fibrillation and treatment or prevention of venothromboembolism.1 Hemorrhage and its related morbidity and mortality are the primary risks associated with these agents.2 A meta-analysis of 13 randomized clinical trials involving 102 707 adults showed major bleeding case-fatality rates of 7.57% with DOACs and 11.05% with warfarin.2 With the approval of 4 DOACs since 2010, management of OAC-associated bleeding has become more complex.
Anderson I, Cifu AS. Management of Bleeding in Patients Taking Oral Anticoagulants. JAMA. 2018;319(19):2032–2033. doi:10.1001/jama.2018.3504
Customize your JAMA Network experience by selecting one or more topics from the list below.